Clinical Report: Clearing Glaucoma's Cellular Clutter
Overview
Preclinical research by Maddineni and colleagues links impaired autophagy and mitophagy to abnormal mitochondrial accumulation, oxidative damage, and retinal ganglion cell (RGC) degeneration in glaucoma models. Torin 2 increased mitophagy and preserved RGC measures in a mouse model without changing intraocular pressure (IOP), and increased RGC survival in an ex vivo human retinal explant model; the findings are not clinical evidence of efficacy.
Background
IOP reduction remains the established approach to preserving visual function in glaucoma, but RGC loss may continue despite pressure control. The European Glaucoma Society states that reducing IOP is the only proven method of preserving visual function. The study examined whether failure to clear damaged mitochondria could contribute to ongoing neurodegeneration. Its experiments used mouse glaucoma models, mitophagy reporter mice, RGC-specific genetic manipulation, and ex vivo human retinal tissue.
Data Highlights
| Experiment or measure | Reported result |
|---|---|
| Mitophagy after five weeks of ocular hypertension | Significantly reduced mitochondrial clearance, detected before measurable RGC loss and axonal degeneration |
| RGC-specific Atg5 disruption, assessed six weeks later | Approximately 39% RGC loss and around 59% loss of healthy optic nerve axons |
| Torin 2 in glucocorticoid-induced mouse glaucoma | Mean pattern electroretinography amplitude: 31.82 µV in treated hypertensive eyes versus 17.36 µV in control-treated hypertensive eyes |
| Torin 2-associated structural measures in the mouse model | 37% increase in RGC number and 51% increase in morphologically intact axons |
| Torin 2 in ex vivo human retinal explants | Approximately 49.7% increase in RGC survival under neurotrophic factor-deprived conditions |
Key Findings
- Sustained IOP elevation was associated with swollen mitochondria with disorganized or fragmented cristae in RGCs and optic nerve axons, alongside increased markers of mitochondrial accumulation and oxidative DNA damage.
- Mitophagy reporter experiments detected reduced mitochondrial clearance after five weeks of ocular hypertension, before detectable RGC loss and axonal degeneration; impairment persisted after neurodegeneration was established.
- RGC-specific disruption of Atg5 was followed by abnormal mitochondrial accumulation, oxidative DNA damage, impaired RGC function, approximately 39% RGC loss, and around 59% loss of healthy optic nerve axons.
- In the glucocorticoid-induced mouse model, intravitreal Torin 2 increased mitophagy and preserved RGC function without altering IOP; treated hypertensive eyes had higher mean pattern electroretinography amplitudes than control-treated hypertensive eyes.
- Torin 2 was associated with a 37% increase in RGC number and a 51% increase in morphologically intact axons in the mouse model, and approximately 49.7% greater RGC survival in ex vivo human retinal explants.
- The authors noted that some neuroprotection in the myocilin model may have resulted from an accompanying IOP reduction and that broad mTOR inhibition may complicate translation; they proposed further study of more selective autophagy or mitophagy modulators.
Clinical Implications
The findings are preclinical and do not establish Torin 2 as a treatment for patients with glaucoma. The authors identify selective autophagy or mitophagy modulators and pathway-specific interventions as subjects for future research; current clinical guidance continues to identify IOP reduction as the proven means of preserving visual function.
Conclusion
The study associates impaired mitochondrial clearance with RGC degeneration and reports protective effects of autophagy activation in experimental models. Whether selective targeting of these pathways can provide clinical neuroprotection remains to be established.
Related Resources & Content
- Maddineni P, et al., Molecular Neurodegeneration, year not provided -- Study of autophagy, mitophagy, and glaucoma described in the supplied article
- European Glaucoma Society, 2025 -- Terminology and Guidelines for Glaucoma, 6th Edition
- Heijl A, et al., Archives of Ophthalmology, 2002 -- Reduction of Intraocular Pressure and Glaucoma Progression: Results From the Early Manifest Glaucoma Trial
- Glaucoma Physician, 2020 -- Identifying Cell Degeneration in Glaucoma
- Glaucoma Physician — Treatment of Severe Ocular Surface Disease in the Glaucoma Patient Recommendations
- Ophthalmology Management — Mitigating Ocular Surface Disease in Patients With Glaucoma
- Ophthalmology Management — Mitigating Ocular Surface Disease in Patients With Glaucoma
- European Glaucoma Society – Terminology and Guidelines for Glaucoma, 6th Edition
- Reduction of Intraocular Pressure and Glaucoma Progression: Results From the Early Manifest Glaucoma Trial
- Reduction of Intraocular Pressure and Glaucoma Progression: Results From the Early Manifest Glaucoma Trial
- Evaluating Primary Treatment for People with Advanced Glaucoma: Five-Year Results of the Treatment of Advanced Glaucoma Study
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.